BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Apple Restores Telegram to App Store After Content Policy Violation 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Telegram Restored on Apple App Store After Temporary Removal 
(4) - EconoTimes)
CAMBRIDGE, Mass., March 30, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on March 30, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to twelve individuals hired by Sarepta in March 2018. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 42,443 shares of Sarepta's common stock. The options have an exercise price of $74.09 per share. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]
